Saturday, May 26, 2012

Phase 3 Clinical Trial Next Generation Dihydroergotamine With Advanced Inhaler Delivery Offer Migrai

By MAGNUM, the National Migraine Assoc. Saturday, November 29, 2008

MAP Pharmaceuticals Embarks On Phase 3 Clinical Trial in Patients With Migraine Disease


WASHINGTON, DC; August 14th, 2008-Football season is here again, and with it so are the weekend rituals followed by those Monday morning quarterbacking sessions with our co-workers and friends.


This made us realize while advocating for Migraine disease over the years we have had the opportunity to meet some of the NFL's greatest players! Often this opportunity happened when Michael John had his art featured in MAGNUM Migraine Art Awareness Exhibits, or his photography was donated on behalf of MAGNUM at various Washington, D.C. fund risers for cancer to the victims of 911, which on occasion offered us the pleasure to meet many NLF football players in person. Some of the most memorable were All-Pro Washington Redskins Darrell Green and John Riggins, both wearing their Super Bowl rings to boot!


Continue reading Phase 3 Clinical Trial Next Generation Dihydroergotamine With Advanced Inhaler Delivery Offer Migraineurs More Choice.

 

MAGNUM Board Member & Health Advocate Teri Robert Visits DC

Ask a Question

Get answers from our experts and community members.

Btn_ask_question_med
View all questions (4349) >
By MAGNUM, the National Migraine Assoc.— Last Modified: 09/04/10, First Published: 11/29/08